Last updated on April 19, 2014 at 21:20 EDT

Beijing PLA General Hospital treats more than 1,000 neurosurgery patients using VISIUS(R) Surgical Theatre

November 15, 2012

iMRI assists in determining if all of tumor is removed

WINNIPEG, Nov. 15, 2012 /PRNewswire/ – IMRIS Inc. (NASDAQ: IMRS; TSX: IM)
(“IMRIS” or the “Company”) today announced PLA General Hospital in
Beijing, China, has surpassed a major milestone of treating more than
1,000 neurosurgery patients using a VISIUS(®) Surgical Theatre. PLA General Hospital was the first hospital in China
to install a VISIUS Surgical Theatre featuring a ceiling mounted,
high-field intraoperative MR (iMRI) in February 2009.

“With the VISIUS Surgical Theatre, we recognized surgical precision
enhancement and the ability to improve the extent of resection and
reduce re-surgeries in tumor cases without moving the patient,” said
Dr. Bainian Xu, hospital chief neurosurgeon. “Use of iMRI,” he said,
“provided us the three M’s of operation: maximum removal of lesion,
minimum injury to neurologic function, and marvelous patient recovery.”

Dr. Xu added, “The percentage of patients with total resection (tumor
removal) in our department has been enhanced to 89%, and in 31% of all
cases we resected additional tumor after an intraoperative MR scan that
would have otherwise been missed.” He also said this experience in
improved precision is leading to fast developing changes in operational
theories and methods for deep-brain, functional area and skull base
procedures at their hospital.

The types of neurosurgical procedures included in the 1,000 cases are
gliomas, pituitary adenomas, vascular lesions, frameless biopsies,
skull-based procedures, metastatic tumor surgeries, epilepsy, and

This past April, Dr. Xiaolei Chen, associate professor of neurosurgery
at PLA General Hospital, presented preliminary results of the first
randomized clinical trial that studied the resection of low-grade
insular glioma using high-field 1.5T iMRI at the American Association
of Neurological Surgeons (AANS) annual meeting. The study results show
significantly greater extent of tumor resection, better rates of total
resection and better long-term outcomes for the group undergoing
surgery with iMRI in a VISIUS Surgical Theatre, compared to the control
group without iMRI.


IMRIS (NASDAQ: IMRS; TSX: IM) is a global leader in providing image
guided therapy solutions through its VISIUS Surgical Theatre – a
revolutionary, multifunctional surgical environment that provides
unmatched intraoperative vision to clinicians to assist in decision
making and enhance precision in treatment. VISIUS Surgical Theatres
serve the neurosurgical, cardiovascular and cerebrovascular markets and
have been selected by leading medical institutions around the world.




Source: PR Newswire